Leonardo Josué Castro-Muñoz

This study identifies CDC7 and POU2F1 as direct targets of EBNA1 in EBV+ epithelial cancers using VK1727 inhibition, revealing new therapeutic strategies.

This study uses an ex vivo PBMC model to show that monocyte and Treg dynamics determine EBV infection outcomes, with LIPA and Tregs playing key roles in antiviral responses and LCL outgrowth.

This study shows H2A.Z.1 works with EBNA1 to maintain EBV latency by regulating chromatin structure and gene expression.

This study identifies PLOD1 as a post-translational regulator of EBNA1 protein stability and function in EBV latency, showing that PLOD1 depletion reduces EBNA1 levels and inhibits viral replication and episome maintenance.